My Bibliography

select

Lustberg M, Wu X, Fernández-Martínez JL, de Andrés-Galiana EJ, Philips S, Leibowitz J, Schneider B, Sonis S. Leveraging GWAS data derived from a large cooperative group trial to assess the risk of taxane-induced peripheral neuropathy (TIPN) in patients being treated for breast cancer: Part 2-functional implications of a SNP cluster associated with TIPN risk in patients being treated for breast cancer. Support Care Cancer. 2023 Feb 21;31(3):178. doi: 10.1007/s00520-023-07617-6. PubMed PMID: 36809570.

select

Ardeshir-Larijani F, Schneider BP, Althouse SK, Radovich M, Masood A, Perna F, Salman H, Loehrer PJ. Clinicogenomic Landscape of Metastatic Thymic Epithelial Tumors. JCO Precis Oncol. 2023 Feb;7:e2200465. doi: 10.1200/PO.22.00465. PubMed PMID: 36787505; PubMed Central PMCID: PMC10309539.

select

Lustberg M, Wu X, Fernández-Martínez JL, de Andrés-Galiana EJ, Philips S, Leibowitz J, Schneider B, Sonis S. Identification of a SNP cluster associated with taxane-induced peripheral neuropathy risk in patients being treated for breast cancer using GWAS data derived from a large cooperative group trial. Support Care Cancer. 2023 Jan 28;31(2):139. doi: 10.1007/s00520-023-07595-9. PubMed PMID: 36707490.

select

Rowe EJ, Shugg T, Ly RC, Philips S, Rosenman MB, Callaghan JT, Radovich M, Overholser BR, Schneider BP, Tisdale JE, Skaar TC. Association of QT interval-prolonging drugs with clinical trial eligibility in patients with advanced cancer. Front Cardiovasc Med. 2022;9:894623. doi: 10.3389/fcvm.2022.894623. eCollection 2022. PubMed PMID: 36588548; PubMed Central PMCID: PMC9798408.

select

Wu X, Shen F, Jiang G, Xue G, Philips S, Gardner L, Cunningham G, Bales C, Cantor E, Schneider BP. A non-coding GWAS variant impacts anthracycline-induced cardiotoxic phenotypes in human iPSC-derived cardiomyocytes. Nat Commun. 2022 Nov 22;13(1):7171. doi: 10.1038/s41467-022-34917-y. PubMed PMID: 36418322; PubMed Central PMCID: PMC9684507.

select

Sharma S, Opyrchal M, Lu X. Harnessing tumorous flaws for immune supremacy: is miRNA-155 the weak link in breast cancer progression?. J Clin Invest. 2022 Oct 3;132(19). doi: 10.1172/JCI163010. PubMed PMID: 36189796; PubMed Central PMCID: PMC9525109.

select

Cantor EL, Shen F, Jiang G, Tan Z, Cunningham GM, Wu X, Philips S, Schneider BP. Passage number affects differentiation of sensory neurons from human induced pluripotent stem cells. Sci Rep. 2022 Sep 23;12(1):15869. doi: 10.1038/s41598-022-19018-6. PubMed PMID: 36151116; PubMed Central PMCID: PMC9508090.

select

Radovich M, Solzak JP, Wang CJ, Hancock BA, Badve S, Althouse SK, Bray SM, Storniolo AMV, Ballinger TJ, Schneider BP, Miller KD. Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2022 Aug 2;28(15):3235-3241. doi: 10.1158/1078-0432.CCR-21-3078. PubMed PMID: 35551360; PubMed Central PMCID: PMC9357180.

select

Schneider BP, Ballinger TJ, Jiang G, Shen F, Kassem N, Miller KD. Reply to K. Nozawa et al. J Clin Oncol. 2022 Jun 10;40(17):1963-1964. doi: 10.1200/JCO.22.00288. Epub 2022 Mar 31. PubMed PMID: 35357884.

select

Ly RC, Shugg T, Ratcliff R, Osei W, Lynnes TC, Pratt VM, Schneider BP, Radovich M, Bray SM, Salisbury BA, Parikh B, Sahinalp SC, Numanagić I, Skaar TC. Analytical Validation of a Computational Method for Pharmacogenetic Genotyping from Clinical Whole Exome Sequencing. J Mol Diagn. 2022 Jun;24(6):576-585. doi: 10.1016/j.jmoldx.2022.03.008. Epub 2022 Apr 20. PubMed PMID: 35452844; PubMed Central PMCID: PMC9227988.

select

Ballinger TJ, Jiang G, Shen F, Miller KD, Sledge GW Jr, Schneider BP. Impact of African ancestry on the relationship between body mass index and survival in an early-stage breast cancer trial (ECOG-ACRIN E5103). Cancer. 2022 Jun 1;128(11):2174-2181. doi: 10.1002/cncr.34173. Epub 2022 Mar 14. PubMed PMID: 35285940; PubMed Central PMCID: PMC9086123.

select

Barroso-Sousa R, Tarantino P, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy KJ, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I, Tolaney SM. Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. NPJ Breast Cancer. 2022 Feb 16;8(1):18. doi: 10.1038/s41523-022-00385-2. PubMed PMID: 35173164; PubMed Central PMCID: PMC8850608.

select

Rosenberg SM, O'Neill A, Sepucha K, Miller KD, Dang CT, Northfelt DW, Sledge GW, Schneider BP, Partridge AH. Quality of Life Following Receipt of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer. JAMA Netw Open. 2022 Feb 1;5(2):e220254. doi: 10.1001/jamanetworkopen.2022.0254. PubMed PMID: 35226083; PubMed Central PMCID: PMC8886546.

select

Shugg T, Ly RC, Rowe EJ, Philips S, Hyder MA, Radovich M, Rosenman MB, Pratt VM, Callaghan JT, Desta Z, Schneider BP, Skaar TC. Clinical Opportunities for Germline Pharmacogenetics and Management of Drug-Drug Interactions in Patients With Advanced Solid Cancers. JCO Precis Oncol. 2022 Feb;6:e2100312. doi: 10.1200/PO.21.00312. PubMed PMID: 35201852; PubMed Central PMCID: PMC9848543.

select

Schneider BP, Jiang G, Ballinger TJ, Shen F, Chitambar C, Nanda R, Falkson C, Lynce FC, Gallagher C, Isaacs C, Blaya M, Paplomata E, Walling R, Daily K, Mahtani R, Thompson MA, Graham R, Cooper ME, Pavlick DC, Albacker LA, Gregg J, Solzak JP, Chen YH, Bales CL, Cantor E, Hancock BA, Kassem N, Helft P, O'Neil B, Storniolo AMV, Badve S, Miller KD, Radovich M. BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. J Clin Oncol. 2022 Feb 1;40(4):345-355. doi: 10.1200/JCO.21.01657. Epub 2021 Dec 15. PubMed PMID: 34910554.

select

Quintanilha JCF, Wang J, Sibley AB, Jiang C, Etheridge AS, Shen F, Jiang G, Mulkey F, Patel JN, Hertz DL, Dees EC, McLeod HL, Bertagnolli M, Rugo H, Kindler HL, Kelly WK, Ratain MJ, Kroetz DL, Owzar K, Schneider BP, Lin D, Innocenti F. Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. Br J Cancer. 2022 Feb;126(2):265-274. doi: 10.1038/s41416-021-01557-w. Epub 2021 Oct 6. PubMed PMID: 34616010; PubMed Central PMCID: PMC8770703.

select

Powell NR, Shugg T, Ly RC, Albany C, Radovich M, Schneider BP, Skaar TC. Life-Threatening Docetaxel Toxicity in a Patient With Reduced-Function CYP3A Variants: A Case Report. Front Oncol. 2021;11:809527. doi: 10.3389/fonc.2021.809527. eCollection 2021. PubMed PMID: 35174070; PubMed Central PMCID: PMC8841796.

select

Cunningham GM, Shen F, Wu X, Cantor EL, Gardner L, Philips S, Jiang G, Bales CL, Tan Z, Liu Y, Wan J, Fehrenbacher JC, Schneider BP. The impact of SBF2 on taxane-induced peripheral neuropathy. PLoS Genet. 2022 Jan;18(1):e1009968. doi: 10.1371/journal.pgen.1009968. eCollection 2022 Jan. PubMed PMID: 34986146; PubMed Central PMCID: PMC8765656.

select

Quintanilha JCF, Wang J, Sibley AB, Jiang C, Etheridge AS, Shen F, Jiang G, Mulkey F, Patel JN, Hertz DL, Dees EC, McLeod HL, Bertagnolli M, Rugo H, Kindler HL, Kelly WK, Ratain MJ, Kroetz DL, Owzar K, Schneider BP, Lin D, Innocenti F. Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. Br J Cancer. 2022 Jan;126(1):162. doi: 10.1038/s41416-021-01617-1. PubMed PMID: 34853435; PubMed Central PMCID: PMC8727676.

select

Van Poznak C, Reynolds EL, Estilo CL, Hu M, Schneider BP, Hertz DL, Gersch C, Thibert J, Thomas D, Banerjee M, Rae JM, Hayes DF. Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancer. Oral Dis. 2022 Jan;28(1):193-201. doi: 10.1111/odi.13746. Epub 2020 Dec 14. PubMed PMID: 33274559; PubMed Central PMCID: PMC8284838.

select

Zhou Z, Van der Jeught K, Fang Y, Yu T, Li Y, Ao Z, Liu S, Zhang L, Yang Y, Eyvani H, Cox ML, Wang X, He X, Ji G, Schneider BP, Guo F, Wan J, Zhang X, Lu X. An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity. Nat Biomed Eng. 2021 Nov;5(11):1320-1335. doi: 10.1038/s41551-021-00805-x. Epub 2021 Nov 1. PubMed PMID: 34725507; PubMed Central PMCID: PMC8647932.

select

Sardesai SD, Thomas A, Gallagher C, Lynce F, Ottaviano YL, Ballinger TJ, Schneider BP, Storniolo AM, Bauchle A, Althouse SK, Perkins SM, Masters AR, Stratford RE Jr, Dong Z, Liu JY, Zhang JT, Miller KD. Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC. Clin Cancer Res. 2021 Nov 1;27(21):5810-5817. doi: 10.1158/1078-0432.CCR-21-0493. Epub 2021 Aug 16. PubMed PMID: 34400413.

select

Mamdani H, Schneider B, Perkins SM, Burney HN, Kasi PM, Abushahin LI, Birdas T, Kesler K, Watkins TM, Badve SS, Radovich M, Jalal SI. A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium Study. Front Oncol. 2021;11:736620. doi: 10.3389/fonc.2021.736620. eCollection 2021. PubMed PMID: 34604072; PubMed Central PMCID: PMC8484871.

select

Newman L, Fejerman L, Pal T, Mema E, McGinty G, Cheng A, Levy M, Momoh A, Troester M, Schneider B, McNeil L, Davis M, Babagbemi K, Hunt K. Breast Cancer Disparities Through the Lens of the COVID-19 Pandemic. Curr Breast Cancer Rep. 2021;13(3):110-112. doi: 10.1007/s12609-021-00419-x. Epub 2021 Aug 6. Review. PubMed PMID: 34394841; PubMed Central PMCID: PMC8344389.

select

Ruddy KJ, Zheng Y, Tayob N, Hu J, Dang CT, Yardley DA, Isakoff SJ, Valero VV, Faggen MG, Mulvey TM, Bose R, Sella T, Weckstein DJ, Wolff AC, Reeder-Hayes KE, Rugo HS, Ramaswamy B, Zuckerman DS, Hart LL, Gadi VK, Constantine M, Cheng KL, Briccetti FM, Schneider BP, Merrill Garrett A, Kelly Marcom P, Albain KS, DeFusco PA, Tung NM, Ardman BM, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu MC, Rosenberg S, DeMeo MK, Burstein HJ, Winer EP, Krop IE, Partridge AH, Tolaney SM. Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Res Treat. 2021 Aug;189(1):103-110. doi: 10.1007/s10549-021-06267-8. Epub 2021 Jun 12. PubMed PMID: 34120223.

select

Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy K, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I. Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. J Clin Oncol. 2021 Jul 20;39(21):2375-2385. doi: 10.1200/JCO.20.03398. Epub 2021 Jun 2. PubMed PMID: 34077270.

select

Stout LA, Kassem N, Hunter C, Philips S, Radovich M, Schneider BP. Identification of germline cancer predisposition variants during clinical ctDNA testing. Sci Rep. 2021 Jul 1;11(1):13624. doi: 10.1038/s41598-021-93084-0. PubMed PMID: 34211039; PubMed Central PMCID: PMC8249601.

select

Scott EN, Wright GEB, Drögemöller BI, Hasbullah JS, Gunaretnam EP, Miao F, Bhavsar AP, Shen F, Schneider BP, Carleton BC, Ross CJD. Transcriptome-wide association study uncovers the role of essential genes in anthracycline-induced cardiotoxicity. NPJ Genom Med. 2021 May 21;6(1):35. doi: 10.1038/s41525-021-00199-4. PubMed PMID: 34021165; PubMed Central PMCID: PMC8140137.

select

Ballinger TJ, Jiang G, Kassem N, Radovich M, Schneider BP. Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158. Clin Cancer Res. 2021 Feb 15;27(4):1195-1199. doi: 10.1158/1078-0432.CCR-20-3341. Epub 2020 Nov 16. PubMed PMID: 33199491.

select

Li Y, Sun Y, Kulke M, Hechler T, Van der Jeught K, Dong T, He B, Miller KD, Radovich M, Schneider BP, Pahl A, Zhang X, Lu X. Targeted immunotherapy for HER2-low breast cancer with 17p loss. Sci Transl Med. 2021 Feb 10;13(580). doi: 10.1126/scitranslmed.abc6894. PubMed PMID: 33568521; PubMed Central PMCID: PMC8351376.

select

Yu T, Dong T, Eyvani H, Fang Y, Wang X, Zhang X, Lu X. Metabolic interventions: A new insight into the cancer immunotherapy. Arch Biochem Biophys. 2021 Jan 15;697:108659. doi: 10.1016/j.abb.2020.108659. Epub 2020 Nov 2. Review. PubMed PMID: 33144083; PubMed Central PMCID: PMC8638212.

select

Fang Y, Wang L, Wan C, Sun Y, Van der Jeught K, Zhou Z, Dong T, So KM, Yu T, Li Y, Eyvani H, Colter AB, Dong E, Cao S, Wang J, Schneider BP, Sandusky GE, Liu Y, Zhang C, Lu X, Zhang X. MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation. J Clin Invest. 2021 Jan 4;131(1). doi: 10.1172/JCI140837. PubMed PMID: 32990678; PubMed Central PMCID: PMC7773365.

select

Filho OM, Giobbie-Hurder A, Lin NU, Faggen M, Come S, Openshaw T, Constantine M, Walsh J, Freedman RA, Schneider B, Burstein HJ, Mayer EL. A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer. Breast Cancer Res Treat. 2021 Jan;185(1):135-144. doi: 10.1007/s10549-020-05928-4. Epub 2020 Oct 6. PubMed PMID: 33025482.

select

Leone JP, Emblem KE, Weitz M, Gelman RS, Schneider BP, Freedman RA, Younger J, Pinho MC, Sorensen AG, Gerstner ER, Harris G, Krop IE, Morganstern D, Sohl J, Hu J, Kasparian E, Winer EP, Lin NU. Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases. Breast Cancer Res. 2020 Nov 30;22(1):131. doi: 10.1186/s13058-020-01372-w. PubMed PMID: 33256829; PubMed Central PMCID: PMC7706261.

select

Schneider BP, Stout LA, Philips S, Schroeder C, Scott SF, Hunter C, Kassem N, Kiel PJ, Radovich M. Implications of Incidental Germline Findings Identified In the Context of Clinical Whole Exome Sequencing for Guiding Cancer Therapy. JCO Precis Oncol. 2020 Nov;4:1109-1121. doi: 10.1200/PO.19.00354. PubMed PMID: 35050776.

select

Kassem N, Stout LA, Hunter C, Schneider B, Radovich M. Precision Prevention: The Current State and Future of Genomically Guided Cancer Prevention. JCO Precis Oncol. 2020 Nov;4:96-108. doi: 10.1200/PO.19.00278. PubMed PMID: 35050732.

select

Chinh K, Secinti E, Johns SA, Hirsh AT, Miller KD, Schneider B, Storniolo AM, Mina L, Newton EV, Champion VL, Mosher CE. Relations of Mindfulness and Illness Acceptance With Psychosocial Functioning in Patients With Metastatic Breast Cancer and Caregivers. Oncol Nurs Forum. 2020 Nov 1;47(6):739-752. doi: 10.1188/20.ONF.739-752. PubMed PMID: 33063774; PubMed Central PMCID: PMC7791760.

select

Mosher CE, Krueger E, Hirsh AT, Miller KD, Ballinger TJ, Storniolo AM, Schneider BP, Newton EV, Champion VL, Johns SA. Protocol of a randomized trial of acceptance and commitment therapy for fatigue interference in metastatic breast cancer. Contemp Clin Trials. 2020 Nov;98:106168. doi: 10.1016/j.cct.2020.106168. Epub 2020 Oct 7. PubMed PMID: 33038501; PubMed Central PMCID: PMC7686157.

select

Chiorean EG, Perkins SM, Strother RM, Younger A, Funke JM, Shahda SG, Hahn NM, Sandrasegaran K, Jones DR, Skaar TC, Schneider BP, Sweeney CJ, Matei DE. Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors. Mol Cancer Ther. 2020 Oct;19(10):2155-2162. doi: 10.1158/1535-7163.MCT-20-0277. Epub 2020 Aug 26. PubMed PMID: 32847973; PubMed Central PMCID: PMC7541675.

select

Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, Kelley MR, Lavino A, Lustberg MB, Paice JA, Schneider BP, Lavoie Smith EM, Smith ML, Smith TJ, Wagner-Johnston N, Hershman DL. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol. 2020 Oct 1;38(28):3325-3348. doi: 10.1200/JCO.20.01399. Epub 2020 Jul 14. PubMed PMID: 32663120.

select

Radovich M, Jiang G, Hancock BA, Chitambar C, Nanda R, Falkson C, Lynce FC, Gallagher C, Isaacs C, Blaya M, Paplomata E, Walling R, Daily K, Mahtani R, Thompson MA, Graham R, Cooper ME, Pavlick DC, Albacker LA, Gregg J, Solzak JP, Chen YH, Bales CL, Cantor E, Shen F, Storniolo AMV, Badve S, Ballinger TJ, Chang CL, Zhong Y, Savran C, Miller KD, Schneider BP. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial. JAMA Oncol. 2020 Sep 1;6(9):1410-1415. doi: 10.1001/jamaoncol.2020.2295. PubMed PMID: 32644110; PubMed Central PMCID: PMC7349081.

select

Chua KC, Xiong C, Ho C, Mushiroda T, Jiang C, Mulkey F, Lai D, Schneider BP, Rashkin SR, Witte JS, Friedman PN, Ratain MJ, McLeod HL, Rugo HS, Shulman LN, Kubo M, Owzar K, Kroetz DL. Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy. Clin Pharmacol Ther. 2020 Sep;108(3):625-634. doi: 10.1002/cpt.1958. Epub 2020 Aug 2. PubMed PMID: 32562552; PubMed Central PMCID: PMC7718413.

select

Ly RC, Schmidt RE, Kiel PJ, Pratt VM, Schneider BP, Radovich M, Offer SM, Diasio RB, Skaar TC. Severe Capecitabine Toxicity Associated With a Rare DPYD Variant Identified Through Whole-Genome Sequencing. JCO Precis Oncol. 2020;4. doi: 10.1200/PO.20.00067. eCollection 2020. PubMed PMID: 32923881; PubMed Central PMCID: PMC7446391.

select

Hancock BA, Chen YH, Solzak JP, Ahmad MN, Wedge DC, Brinza D, Scafe C, Veitch J, Gottimukkala R, Short W, Atale RV, Ivan M, Badve SS, Schneider BP, Lu X, Miller KD, Radovich M. Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers. Breast Cancer Res. 2019 Aug 5;21(1):87. doi: 10.1186/s13058-019-1171-7. PubMed PMID: 31383035; PubMed Central PMCID: PMC6683504.

select

Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, Schneider BP, Shen F, Fuhrman K, Baltay M, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer B, Partridge AH, Hudis CA, Krop IE, Burstein HJ, Winer EP. Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Clin Oncol. 2019 Aug 1;37(22):1868-1875. doi: 10.1200/JCO.19.00066. Epub 2019 Apr 2. PubMed PMID: 30939096; PubMed Central PMCID: PMC7587424.

select

Zhang KJ, Schneider BP, Albany C. Microsatellite Instability May Predict Response to Sipuleucel-T in Patients With Prostate Cancer. Clin Genitourin Cancer. 2019 Jun;17(3):238-239. doi: 10.1016/j.clgc.2019.03.016. Epub 2019 Apr 1. PubMed PMID: 31015016.

select

Swart M, Stansberry WM, Pratt VM, Medeiros EB, Kiel PJ, Shen F, Schneider BP, Skaar TC. Analytical Validation of Variants to Aid in Genotype-Guided Therapy for Oncology. J Mol Diagn. 2019 May;21(3):491-502. doi: 10.1016/j.jmoldx.2019.01.009. Epub 2019 Feb 20. PubMed PMID: 30794985; PubMed Central PMCID: PMC6504676.

select

Saad ED, Squifflet P, Burzykowski T, Quinaux E, Delaloge S, Mavroudis D, Perez E, Piccart-Gebhart M, Schneider BP, Slamon D, Wolmark N, Buyse M. Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. Lancet Oncol. 2019 Mar;20(3):361-370. doi: 10.1016/S1470-2045(18)30750-2. Epub 2019 Jan 29. PubMed PMID: 30709633; PubMed Central PMCID: PMC7050571.

select

Liu Y, Xu J, Choi HH, Han C, Fang Y, Li Y, Van der Jeught K, Xu H, Zhang L, Frieden M, Wang L, Eyvani H, Sun Y, Zhao G, Zhang Y, Liu S, Wan J, Huang C, Ji G, Lu X, He X, Zhang X. Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer. Nat Commun. 2018 Nov 9;9(1):4718. doi: 10.1038/s41467-018-07264-0. PubMed PMID: 30413718; PubMed Central PMCID: PMC6226492.

select

Kiel PJ, Radovich M, Schneider BP, Logan TF. Sustained Exceptional Response to Poly (ADP-Ribose) Polymerase Inhibition Plus Temozolomide in Metastatic Melanoma With DNA Repair Deficiency. JCO Precis Oncol. 2018 Nov;2:1-7. doi: 10.1200/PO.18.00150. PubMed PMID: 35135169.